Analysts Boost Targets as Colgate-Palmolive Posts Strong Quarterly Performance

Colgate-Palmolive has demonstrated notable operational resilience in a turbulent consumer goods market, surpassing expectations with its latest quarterly earnings. The company’s core business continues to thrive, even as a significant non-cash impairment charge in its skincare unit created a one-time accounting effect. Following substantial price target revisions from major banks, investors are assessing the durability of the firm’s current momentum.

Revised Forecasts from Financial Institutions

The response from Wall Street analysts was swift following the earnings release. Multiple institutions raised their valuation models on Monday. Both Bank of America and Morgan Stanley increased their price targets to $100. Morgan Stanley maintained its “Overweight” rating on the shares, citing improved organic growth and solid profitability within the defensive consumer staples sector.

Wells Fargo also lifted its target to $94, though it retained a neutral stance. A more cautious view came from Deutsche Bank, which adjusted its target upward to $90 but continues to recommend a “Hold” position on the stock.

Earnings Exceed Consensus Estimates

The consumer products giant delivered a convincing performance for the fourth quarter of 2025, beating market forecasts on both revenue and profit. Adjusted earnings per share came in at $0.95, exceeding the consensus estimate of $0.91. Revenue climbed 5.8% year-over-year to $5.23 billion.

Should investors sell immediately? Or is it worth buying Colgate-Palmolive?

This positive result was primarily driven by robust organic growth and a strong gross margin of 60.2%. However, under GAAP accounting standards, the company reported a net loss. This was due to an extraordinary, non-cash impairment charge of $794 million related to the skincare brands Filorga and EltaMD. Market participants are placing far greater emphasis on the underlying operational performance than on this accounting anomaly.

Portfolio Performance and Current Valuation

Within the company’s portfolio, the Hill’s Pet Nutrition division proved once again to be a reliable growth engine, posting revenue growth of over five percent. In a market environment where investors are increasingly seeking defensive plays, Colgate-Palmolive benefits from its strong market positioning.

The stock is currently trading at €74.77, having gained approximately 2.82% over the past seven trading days. This represents a stabilization after a weaker month, though the shares remain about 17% below their 52-week high of €90.34 reached last year.

Management’s Forward-Looking Guidance

For the 2026 fiscal year, management is forecasting organic sales growth in a range of one to four percent. Currency-adjusted earnings growth is projected to be between six and eight percent. This guidance underscores the company’s clear focus on continuing its profitability strategy alongside moderate top-line expansion.